Sanofi's diabetes drug Toujeo gets U.S. approval, label disappoints

French drugmaker Sanofi SA's new Toujeo diabetes drug won U.S. regulatory approval, but with wording on its prescribing label that analysts say could make marketing difficult. Toujeo is a more potent follow-up to the drugmaker's top-selling Lantus insulin product, which accounts for a fifth of Sanofi (LSE: 0O59.L - news) sales. Sanofi is hoping to convert patients to Toujeo as Lantus is due to ...

Diabetes help and advice